Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings in Brief: Imatron

This article was originally published in The Gray Sheet

Executive Summary

Imatron: Completes $16 mil. private placement, funds from which will go to its HeartScan Imaging Inc. subsidiary, which provides coronary artery disease risk assessment using Imatron's Ultrafast CT scanner. Proceeds will allow HeartScan to "implement its plan for accelerating the opening of new centers" and "will allow us to establish HeartScan as a separate business which we expect will provide Imatron with a very strong continuing source of orders for our Ultrafast CT scanners as well as continued significant participation in HeartScan's service revenue stream," Imatron says. Investors in the placement include: SC Fundamental Value Fund, Cramer Rosenthal McGlynn, and Gruber & McBaine...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel